Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04657-5. Online ahead of print.

Authors

Romain Sechaud¹, Helen Gu², Gholamreza Rahmanzadeh³, Amanda Taylor², Ovidiu Chiparus², Gopal Krishna Sharma⁴, Astrid Breitschaft⁵, Hans D Menssen³

Affiliations

¹ Novartis Pharma AG, 4002, Basel, Switzerland. romain.sechaud@novartis.com.
² Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
³ Novartis Pharma AG, 4002, Basel, Switzerland.
⁴ Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana, 50081, India.
⁵ Parexel International GmbH, 14059, Berlin, Germany.

PMID: 38438807
DOI: 10.1007/s00280-024-04657-5

No abstract available

Publication types

Published Erratum